Evidence map›Paper›PMID 34459128›Full record

ArticleClinical and translational medicine2021

Single-cell transcriptomes reveal heterogeneity of high-grade serous ovarian carcinoma.

Qian Hao, Jiajia Li, Qinghua Zhang, Fei Xu, Bangxiang Xie, Hua Lu, Xiaohua Wu, Xiang Zhou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Qian HaoFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Jiajia LiDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Qinghua ZhangFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Fei XuDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Bangxiang XieBeijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, China.
Hua LuDepartment of Biochemistry & Molecular Biology and Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana.
Xiaohua WuDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Xiang ZhouFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai, China.ORCID 0000-0002-1172-7948
Shanghai Medical College of Fudan University · CNCapital Medical University · CNTulane University · US

Funding

National Natural Science Foundation of China 81702352National Natural Science Foundation of China 81874053National Natural Science Foundation of China 81902660National Natural Science Foundation of China 81972431National Natural Science Foundation of China 82072879
6 · The paper itself

Abstract

backgroundHigh-grade serous ovarian carcinoma (HGSOC) is the most common and aggressive histotype of epithelial ovarian cancer. The heterogeneity and molecular basis of this disease remain incompletely understood.

methodsTo address this question, we have performed a single-cell transcriptomics analysis of matched primary and metastatic HGSOC samples.

resultsA total of 13 571 cells are categorized into six distinct cell types, including epithelial cells, fibroblast cells, T cells, B cells, macrophages, and endothelial cells. A subset of aggressive epithelial cells with hyperproliferative and drug-resistant potentials is identified. Several new markers that are highly expressed in epithelial cells are characterized, and their roles in ovarian cancer cell growth and migration are further confirmed. Dysregulation of multiple signaling pathways, including the translational machinery, is associated with ovarian cancer metastasis through the trajectory analysis. Moreover, single-cell regulatory network inference and clustering (SCENIC) analysis reveals the gene regulatory networks and suggests the JUN signaling pathway as a potential therapeutic target for treatment of ovarian cancer, which is validated using the JUN/AP-1 inhibitor T-5224. Finally, our study depicts the epithelial-fibroblast cell communication atlas and identifies several important receptor-ligand complexes in ovarian cancer development.

conclusionsThis study uncovers new molecular features and the potential therapeutic target of HGSOC, which would advance the understanding and treatment of the disease.

Indexed as

Cell Line, TumorFemaleHumansOvarian NeoplasmsSingle-Cell AnalysisTranscriptomechemoresistancegene regulatory networkintercellular communicationmetastasissingle-cell RNA-seq

Identifiers

PMID34459128
PMCPMC8335963
OpenAlexW3191922386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.